Kardigan, Inc. Common Stock (KARD) - Total Assets
Based on the latest financial reports, Kardigan, Inc. Common Stock (KARD) holds total assets worth $348.19 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore KARD cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Kardigan, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Kardigan, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See KARD net assets for net asset value and shareholders' equity analysis.
Kardigan, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Kardigan, Inc. Common Stock's total assets of $348.19 Million consist of 88.3% current assets and 11.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $23.23 Million | 5.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Kardigan, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KARD market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kardigan, Inc. Common Stock's current assets represent 88.3% of total assets in 2025, an increase from 79.2% in 2024.
- Cash Position: Cash and equivalents constituted 27.9% of total assets in 2025, down from 77.8% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2024.
- Asset Diversification: The largest asset category is intangible assets at 5.9% of total assets.
Kardigan, Inc. Common Stock Competitors by Total Assets
Key competitors of Kardigan, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
NASDAQ:TRAXV
|
USA | $290.58 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Evommune, Inc.
NYSE:EVMN
|
USA | $224.95 Million |
Kardigan, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.42 | - | - |
| Quick Ratio | 9.42 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $266.47 Million | - | - |
Kardigan, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Kardigan, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 4.80 |
| Asset Growth Rate (YoY) | 515.4% |
| Total Assets | $390.94 Million |
| Market Capitalization | $1.88 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Kardigan, Inc. Common Stock's assets at a significant premium (4.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kardigan, Inc. Common Stock's assets grew by 515.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kardigan, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Kardigan, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $390.94 Million | +515.40% |
| 2024-12-31 | $63.53 Million | -- |
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI… Read more